Filter Results

Clinical Studies

Open

  • Identifying Physical Function Trajectories and Biomarkers after Kidney Transplantation Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

    The aims of this study are to identify frailty trajectories and biomarkers of frailty after kidney transplantation. Subjects will be followed beginning immediately prior to kidney transplantation until 1 year after kidney transplantation. Frailty will be prospectively assessed using performance-based measures (Fried criteria and Short Physical Impairment Battery). The relationship between frailty measures and blood levels of promising candidate biomarkers will be analyzed.

  • Senescence, Frailty, and Mesenchymal Stem Cell Functionality in Chronic Kidney Disease: Effect of Senolytic Agents Rochester, Minn.

    To compare the effect of senolytic drugs on cellular senescence, physical ability or frailty, and adipose tissue-derived MSC functionality in patients with chronic kidney disease.

    Primary Objectives:
    To assess the efficacy of a single 3-day treatment regimen with dasatinib and quercetin (senolytic drugs) on clearing senescent adipose-derived MSC in patients with CKD.

    To assess the efficacy of a single 3-day treatment regimen with dasatinib and quercetin (senolytic drugs) on improving adipose-derived MSC functionality in patients with CKD.

    Secondary Objective:
    To assess the short-term effect of a single 3-day treatment regimen with dasatinib and quercetin (senolytic drugs) on frailty index score in patients with CKD.

    To assess the short-term effect of a single 3-day treatment regimen with dasatinib and quercetin (senolytic drugs) on kidney function in patients with CKD.

    To assess the safety and tolerability of a single 3-day treatment regimen with dasatinib 100 mg daily and quercetin 1000 mg total daily in subjects with CKD.

Closed for Enrollment

.